ASP Isotopes Stock Price, News & Analysis

ASP Isotopes (NASDAQ: ASPI) announced a three-year donation to establish a new Photonics Chair at the University of Witwatersrand (Wits) in Johannesburg, with Dr. Angela Dudley named as the inaugural chair.

The endowment will support the Structured Light Laboratory in Wits’ School of Physics, fund photonics research and development, and aim to produce a pipeline of students and candidates for ASP Isotopes as the company scales its quantum enrichment programme.

ASP Isotopes (NASDAQ: ASPI) will hold a quarterly business update conference call and webcast on Friday, November 21, 2025 at 8:30 a.m. Eastern Time.

Investors can join the live webcast at https://events.q4inc.com/attendee/428149635 or dial in: USA/International Toll +1.646.968.2525, USA Toll-Free +1.888.596.4144, Canada Toronto +1.647.495.7514, Conference ID 5073116. Participants should log on or dial in ~5 minutes early. A transcript will be posted afterward on the ASPI investor website.

ASP Isotopes (NASDAQ: ASPI) announced on November 12, 2025 that its wholly owned subsidiary Quantum Leap Energy (QLE) has confidentially submitted a draft Form S-1 to the SEC for a proposed initial public offering of QLE Class A common stock.

The number of shares and the price range have not been determined. The offering is subject to SEC review, market conditions and other customary closing conditions. The release is issued under Rule 135 and does not constitute an offer to sell or solicitation to buy securities.

ASP Isotopes (NASDAQ: ASPI) subsidiary Quantum Leap Energy LLC commenced a private placement of convertible notes with an initial closing of $64.3 million.

The unsecured Notes may convert into QLE common equity prior to maturity at the lower of 80% of the applicable per-share price or a per-share value based on a set valuation cap; maturity is five years from initial closing. QLE cannot repay the Notes before maturity absent a change of control.

Proceeds are intended to build and develop laser enrichment production facilities and for general corporate purposes. The offering was led by ASPI and American Ventures LLC with capital contributions from Eric Trump and Donald Trump Jr.; initial closing is expected on or about November 10, 2025. Canaccord Genuity and Ocean Wall acted as placement agents.

ASP Isotopes (NASDAQ: ASPI) said its UK unit, Quantum Leap Energy Ltd, has begun formal Early Engagement with UK nuclear regulators after the Department for Energy Security and Net Zero confirmed QLE Ltd’s eligibility to enter Early Engagement with the Office for Nuclear Regulation (ONR).

QLE will pursue HALEU production in the UK, prepare site licence and environmental permit applications, continue regulator engagement, and is targeting a potential full licensing pathway within this decade, subject to regulatory and site-specific progress. Rich Deakin joined QLE as SVP and Managing Director, UK Strategic Projects.

ASP Isotopes (NASDAQ: ASPI) subsidiary Quantum Leap Energy completed the acquisition of substantially all assets of One 30 Seven effective Oct 21, 2025 to develop modular Creber Units for treating water-soluble nuclear waste by accelerating beta decay of isotopes like Cesium-137 and Strontium-90. The deal included an international patent application, a consulting agreement with B-Con Engineering, a $150,000 cash payment and 266,113 ASPI shares (~$2.85M), plus potential earnouts of $6M and $11M.

QLE budgeted ~$4.5M to validate a Mini unit and ~$12.5-13M for a Midi/Maxi unit, and agreed to a 6% royalty for 15 years. Regulatory reviews (NRC/DOE) and commercialization milestones apply.

ASP Isotopes (NASDAQ: ASPI) priced an underwritten public offering of 17,167,380 shares of common stock for gross proceeds of approximately $210.3 million, before underwriting discounts, commissions and offering expenses.

The offering is expected to close on October 16, 2025, subject to customary closing conditions. The company granted the underwriters a 30‑day option to purchase additional shares for approximately $31.5 million at the offering price. Cantor and Lucid Capital Markets are joint book‑running managers. The company intends to use net proceeds for general corporate purposes including working capital, operating expenses and capital expenditures.

ASP Isotopes (NASDAQ: ASPI) announced on October 14, 2025 that it is commencing an underwritten public offering of common stock. The offering is subject to market conditions and there is no assurance as to timing, size, or terms.

Cantor and Lucid Capital Markets are acting as joint book-running managers. The offering is being made from a shelf registration statement filed with the SEC on October 14, 2025, which became effective upon filing. A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and will be available at www.sec.gov.

Copies of the preliminary prospectus supplement and prospectus, when available, may be requested from Cantor Fitzgerald or Lucid Capital Markets. This press release is not an offer to sell or a solicitation to buy securities.

ASP Isotopes (NASDAQ: ASPI) announced a supply contract for its largest quantity of enriched silicon-28 to date, with deliveries expected in Q1 2026, and the acquisition of an independent radiopharmacy in Florida, US to expand PET Labs' operations outside South Africa.

The Florida site currently offers SPECT; PET services are expected to start in 2027. The acquisition is described as accretive to 2026 revenues, EBITDA and EPS. PET Labs is pursuing further U.S. expansion and has a non-binding term sheet for another acquisition. An investor access event is scheduled for Nov 12-13, 2025. The company also granted a 30,000-share restricted stock inducement vesting semi-annually over four years.